Cargando…
Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases
The success of small molecule therapeutics that promotes degradation of critical cancer targets has fueled an intense effort to mimic this activity with bispecific molecules called PROTACs (proteolysis targeting chimeras). The simultaneous binding of PROTACs to a ligase and target can induce proximi...
Autores principales: | Luo, Xin, Archibeque, Ivonne, Dellamaggiore, Ken, Smither, Kate, Homann, Oliver, Lipford, James Russell, Mohl, Dane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919295/ https://www.ncbi.nlm.nih.gov/pubmed/35295813 http://dx.doi.org/10.1016/j.isci.2022.103985 |
Ejemplares similares
-
Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation
por: Maniaci, Chiara, et al.
Publicado: (2017) -
Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs
por: Girardini, Miriam, et al.
Publicado: (2019) -
Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders
por: Diehl, Claudia J., et al.
Publicado: (2022) -
Immune regulation by protein ubiquitination: roles of the E3 ligases VHL and Itch
por: Aki, Daisuke, et al.
Publicado: (2018) -
Targeted Degradation of Oncogenic KRAS(G12C) by VHL-Recruiting
PROTACs
por: Bond, Michael J., et al.
Publicado: (2020)